EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Treatment selection and real‐world analysis of immunotherapy with or without chemotherapy in PD‐L1 ‐high metastatic non‐small cell lung cancer

Samuel Smith iD, Steven Kao, Michael Boyer, Michael Franco, Melissa Moore

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16389 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Samuel Smith und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, St Vincent's Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer is the leading cause of cancer death in Australia. Immunotherapy has improved outcomes in patients with metastatic non‐small cell lung cancer (NSCLC). Pembrolizumab is approved in first‐line treatment as single‐agent immunotherapy (SAI) or combination chemoimmunotherapy (CIT). In metastatic NSCLC programmed death‐ligand 1 (PD‐L1) ≥50% either regimen may be used.

Aims

We aim to identify patient and tumour characteristics that influence treatment selection.

Methods

This is a retrospective observational study. Pharmacy records identified patients with metastatic/recurrent NSCLC receiving pembrolizumab at two metropolitan centres in Victoria, Australia, since 2018. Demographics, tumour characteristics, Charlson Comorbidity Index (CCI) and treatment data were collected. Descriptive and multivariate analyses were performed.

Results

Sixty‐one patients had metastatic NSCLC PD‐L1 ≥50% and received pembrolizumab with median age of 65.6 years, Eastern Cooperative Oncology Group 0–1 in 82%. CIT was administered to 23% (14) with no difference in rate of delivery between centres ( P = 0.808). CCI mean score differed (3.38 SAI vs 2.36 CIT, P = 0.042). Patients with high CCI score (≥2) were less likely to receive CIT (OR = 0.15, P = 0.003, 95% confidence interval (CI) 0.04–0.57). Primary tumours over 5 cm were more likely to receive CIT (OR = 3.74, P = 0.043, 95% CI = 1.04–13.42). Site‐specific metastases of liver, brain and pericardial effusion were not associated with CIT.

Conclusions

Patients with higher comorbidity score were less likely to receive CIT, suggesting chemotherapy avoidance in comorbid patients. Larger tumours are associated with CIT use, indicating that oncologists may use tumour size as a surrogate of disease burden. Limitations include small sample size and data cut‐off. Future prospective studies could incorporate comorbid status and a validated disease burden score to stratify patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedImmunotherapyB7-H1 AntigenHumansMaleFemaleRetrospective StudiesAgedMiddle AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsVictoria

Stichwörter der Autor:innen

immunotherapymetastatic diseasenon‐small cell lung cancerpatient selectionreal‐world analysis

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health, School of Medicine, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Medical Oncology, Monash Health, Melbourne, Victoria, Australia.

ORCID-Profile: Samuel Smith

Zitieren

APA

Smith, S., Kao, S., Boyer, M., Franco, M., & Moore, M. (2024). Treatment selection and real‐world analysis of immunotherapy with or without chemotherapy in PD‐L1 ‐high metastatic non‐small cell lung cancer. Internal Medicine Journal. https://doi.org/10.1111/imj.16389

Vancouver

Smith S, Kao S, Boyer M, Franco M, Moore M. Treatment selection and real‐world analysis of immunotherapy with or without chemotherapy in PD‐L1 ‐high metastatic non‐small cell lung cancer. Internal Medicine Journal. 2024. doi:10.1111/imj.16389

BibTeX
@article{Smith2024,
  author = {Smith, Samuel and Kao, Steven and Boyer, Michael and Franco, Michael and Moore, Melissa},
  title = {Treatment selection and real‐world analysis of immunotherapy with or without chemotherapy in PD‐L1 ‐high metastatic non‐small cell lung cancer},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16389}
}
Kostenlos starten →